Plain-English translation of NCT06337084 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new diagnostic tool that combines a radioactive tracer with imaging scans to help detect certain solid tumors. The medication targets cancers that have a specific protein called uPAR on their surface. Researchers want to understand how well this treatment works as a diagnostic tool, how it moves through your body, and whether it's safe.
Current imaging scans sometimes miss tumors or don't show them clearly enough. This medication is designed to light up tumors that other scans might miss, potentially helping doctors find and treat cancer earlier.
You likely qualify if…
You likely don't qualify if…
On Day 1, you will receive a single injection of the medication. You will then have imaging scans (PET/CT) at 2 hours after the injection, and again within Days 3–5 and Days 7–10. Blood samples will be taken on Day 1 and at follow-up visits to measure how the medication moves through your body. You will be followed for one month after the injection to monitor for any side effects.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Australia